ISPOR - EE334 Cost-Effectiveness Analysis of Nivolumab as an Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma at High Risk of Recurrence in Greece

Full Text

EE334 Cost-Effectiveness Analysis of Nivolumab as an Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma at High Risk of Recurrence in Greece

Abstract

Authors

L Ni F Diamantogiannis S Teitsson C Knight

Back to Volume 25, Supplemental Issue 12S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now